Cancer Network spoke with Anna Pavlick, MD, of NYU Langone Health, on the results of a phase II study of poly-ICLC matured dendritic cells for NY-ESO-1 and Mean-A peptide vaccination compared with Montanide.
Cancer Network spoke with Hussein Tawbi, MD, PhD, of MD Anderson Cancer Center, about the efficacy and safety of the combination of nivolumab plus ipilimumab in patients with symptomatic melanoma brain metastases.
Cancer Network spoke with Paul B. Chapman, MD, of Memorial Sloan Kettering Cancer Center, about pursuing adjuvant immunotherapy for patients with melanoma.
Cancer Network spoke with Janice M. Mehnert, MD, of Rutgers Cancer Institute, about the use of immunotherapy vs BRAF/MEK inhibitors in the adjuvant setting for melanoma.
Cancer Network spoke with Thomas Gajewski, MD, PhD, of the University of Chicago Medical Center, about analyzing the tumor microenvironment to guide immunotherapy in melanoma.
Cancer Network spoke with Anna Pavlick, MD, of NYU's Perlmutter Cancer Center, regarding whether there is one correct answer to front-line therapy for the treatment of advanced melanoma.
Cancer Network spoke with Hussein Abdul-Hassan Tawbi, MD, PhD, on the results of a phase II study of oral azacitidine in combination with pembrolizumab in metastatic melanoma.
Cancer Network spoke with Allison Betof Warner, MD, PhD, of Memorial Sloan Kettering Cancer Center, about long-term outcomes and responses to retreatment in patients with melanoma receiving anti-PD1 therapy.
Findings from a pooled analysis of two phase III trials, COMBI-d and COMBI-v, centered on outcomes with first-line dabrafenib plus trametinib vs either agent alone.
The results of the phase II trial examining combination immunotherapy were presented during the ASCO 2019 meeting.